tradingkey.logo

Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology

ReutersFeb 8, 2026 10:09 AM

- Innovent Biologics Inc 1801.HK:

  • INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY

  • INNOVENT BIOLOGICS - INNOVENT WILL RECEIVE A $350 MILLION UPFRONT PAYMENT

  • INNOVENT BIOLOGICS: IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY & COMMERCIAL MILESTONE PAYMENTS UP TO EST $8.5 BILLION CONTINGEN CERTAIN FUTURE EVENTS

  • : INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY

Further company coverage: [1801.HK LLY.N]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI